They also speculated that MiD49/51 can be used as a therapeutic target in diseases involving the dysregulation of mitochondrial dynamics, such as hyperproliferative conditions like cancer and pulmonary arterial hypertension (PAH) [113]. This evidence concerns the gene MIEF2 and pulmonary arterial hypertension.